Twice-Daily Proton Pump Inhibitor Induces Higher Remission Rate in Eosinophilic Esophagitis Than Once-Daily Regimen Regardless of Total Daily Dose

被引:4
|
作者
Muftah, Mayssan [1 ,2 ]
Goldin, Alison H. [1 ,2 ]
Barshop, Kenneth [2 ,3 ]
Blatman, Karen Hsu [2 ,4 ]
Hamilton, Matthew J. [1 ,2 ]
Lo, Wai-Kit [1 ,2 ]
Hornick, Jason L. [2 ,5 ]
Chan, Walter W. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol, Hepatol & Endoscopy, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[4] Brigham & Womens Hosp, Div Allergy & Clin Immunol, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 05期
关键词
eosinophilic esophagitis; proton pump inhibitor; drug dosing; eosinophil; esophageal biopsies; histologic response; MANAGEMENT;
D O I
10.14309/ajg.0000000000002712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: The optimal proton pump inhibitor (PPI) regimen for eosinophilic esophagitis (EoE) is unclear. We compared histologic response rates of different dosing combinations. METHODS: A total of 305 patients with newly diagnosed EoE received standard (omeprazole 20 mg daily), once-daily moderate (40 mg daily), twice-daily moderate (20 mg twice daily), or high (40 mg twice daily) dose PPI for >= 8 weeks. RESULTS: Approximately 42.3% achieved histologic response to PPI, with higher rates for twice-daily (moderate 52.8%/high 54.3%) than once-daily (standard 11.8%/moderate 10%) dosing (P < 0.0001). On multivariable analysis, twice-daily moderate (adjusted odds ratio 6.75, confidence interval 2.53-18.0, P = 0.0008) and high (adjusted odds ratio 12.8, confidence interval 4.69-34.8, P < 0.0001) doses independently predicted histologic response. DISCUSSION: Twice-daily PPI is associated with higher EoE histologic response rates than once-daily regimen.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [1] Retrospective cost analyses of switching from a twice-daily proton pump inhibitor to once-daily esomeprazole
    Crowley, JA
    Brook, R
    Smeeding, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S232 - S232
  • [2] Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
    Balk, Jiska M.
    Haenen, Guido R. M. M.
    Koc, Ozgur M.
    Peters, Ron
    Bast, Aalt
    van der Vijgh, Wim J. F.
    Koek, Ger H.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 137 - 144
  • [3] The Impact of a Twice-daily Versus Once-daily Proton Pump Inhibitor Dosing Regimen on Laryngopharyngeal Reflux Symptoms: A Prospective Randomized Controlled Trial
    Ji, Jeong-Yeon
    Huh, Gene
    Ji, Eunjeong
    Lee, Jin Yi
    Kang, Seung Heon
    Cha, Wonjae
    Jeong, Woo-Jin
    Jung, Young Ho
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2024, 30 (04) : 459 - 467
  • [4] Comparison of Pharmacokinetics and Pathology for Low-Dose Tacrolimus Once-Daily and Twice-Daily in Living Kidney Transplantation: Prospective Trial in Once-Daily Versus Twice-Daily Tacrolimus
    Tsuchiya, Tomohiro
    Ishida, Hideki
    Tanabe, Tatsu
    Shimizu, Tomokazu
    Honda, Kazuho
    Omoto, Kazuya
    Tanabe, Kazunari
    TRANSPLANTATION, 2013, 96 (02) : 198 - 204
  • [5] Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
    Mody, Reema
    Eisenberg, Debra
    Hou, Likun
    Kamat, Siddhesh
    Singer, Joseph
    Gerson, Lauren B.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 161 - 169
  • [6] Conversion of Stable Kidney Transplant Recipients From a Twice-Daily to Once-Daily Everolimus Regimen
    Carmellini, M.
    Collini, A.
    Ruggieri, G.
    Bernini, M.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1312 - 1313
  • [7] Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
    Kinoshita, Yoshikazu
    Kato, Mototsugu
    Fujishiro, Mitsuhiro
    Masuyama, Hironori
    Nakata, Ryo
    Abe, Hisanori
    Kumagai, Shinji
    Fukushima, Yasushi
    Okubo, Yoshiumi
    Hojo, Seiichiro
    Kusano, Motoyasu
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (07) : 834 - 844
  • [8] Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
    Yoshikazu Kinoshita
    Mototsugu Kato
    Mitsuhiro Fujishiro
    Hironori Masuyama
    Ryo Nakata
    Hisanori Abe
    Shinji Kumagai
    Yasushi Fukushima
    Yoshiumi Okubo
    Seiichiro Hojo
    Motoyasu Kusano
    Journal of Gastroenterology, 2018, 53 : 834 - 844
  • [9] Maintenance of Heartburn Symptom Relief in Patients Stepped-Down from Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole MR
    Fass, Ronnie
    Inadomi, John
    Han, Cong
    Mody, Reema
    O'Neil, Janet
    Perez, M. Claudia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S5 - S6
  • [10] Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release
    Fass, Ronnie
    Inadomi, John
    Han, Cong
    Mody, Reema
    O'Neil, Janet
    Perez, M. Claudia
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) : 247 - 253